Curasight uTRACE - Model uPAR-PET - Imaging and Diagnostics Technology
Curasight's uTRACE is a uPAR-PET imaging and diagnostics technology. It is used to find, visualise, and predict whether a cancer is aggressive and if so, how it should be treated. uTRACE has been tested on over 400 patients in several cancer forms and proven to be safe.
-
Most popular related searches
Details:
uPAR – the target
uPAR – urokinase-type plasminogen activator receptor – is a unique biomarker of cancer, as it expresses in cancer cells but not in normal tissue. uPAR is part of the system surrounding the breakdown of normal tissue, meaning part of the process that makes cancer spread and metastasise. It has been shown across most cancer forms, that if uPAR is highly expressed then the cancer is aggressive and needs treatment. These characteristics make uPAR an ideal target for cancer imaging followed by improved diagnosis, risk-stratification, and treatment monitoring. Both Curasight's uTRACE® and uTREAT® approach uPAR to find, visualise and treat cancer cells.
PET imaging
PET imaging – Positron Emission Tomography – is one of the fastest growing technologies in modern medicine and has truly revolutionised cancer medicine. It is a functional imaging technique that uses radioactive substances, known as radiotracers, to visualise and measure changes in metabolic processes and in other physiological activities. The substance used by Curasight's technology uTRACE® for imaging, targets and binds to uPAR, showing an enhanced image of the cancer.
uPAR-PET
Very basically put, using the PET imaging technology to seek out and visualise the uPAR receptor is what Curasight's technology uTRACE® does. Not only finding but also visualising the cancer in an enhanced and intelligent way makes it possible to diagnose the cancer and decide on the best way to treat each individual patient.
Customer reviews
No reviews were found for Curasight uTRACE - Model uPAR-PET - Imaging and Diagnostics Technology. Be the first to review!